翰思艾泰生物医药科技（武汉）股份有限公司（“翰思艾泰-B”，股票代码：03378）于2026年6月2日披露翌日披露报表，宣布于同日通过香港联交所场内回购股份。该公司回购共计40,200股H股，占当日公司现有已发行股份（不包括库存股份）的约0.03%，回购价格区间为每股25.34港元至28.42港元，总金额约106.80万港元。
本次回购完成后，公司持有的库存股份增加至924,900股，公司已发行股份（不包括库存股份）变动后剩余135,293,930股，合计已发行股份总数136,218,830股。根据公告，相关购回授权于2026年2月12日获股东大会通过，可回购总数为13,621,883股。截至目前，公司已根据购回授权累计回购924,900股，占授权通过当日已发行股份（不包括库存股份）数目的约0.679%。
公告中显示，公司已遵守香港联合交易所有限公司证券上市规则以及其他适用法律法规。上述公告由董事长兼执行董事张发明签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.